

Directors: John M. Holliman/54/Exec. Chmn., Principal Executive Officer, Michael E. Mendelsohn/Chmn. - Scientific Advisory Board, Charles A. Dinarello/Member - Scientific Advisory Board, William W. Wardell/Dir., Elwood D. Howse/68/Dir., Augustus A. White/71/Dir., Fredric J. Feldman/67/Dir., Michael D. Casey/62/Dir.

Owners: Insiders/5.30%, James T. Ryaby, Sherry A. Sturman, Augustus A. White, Randolph C. Steer, Dana B. Shinbaum, Elwood D. Howse, Fredric J. Feldman, Les M. Taeger, John M. Holliman, Michael D. Casey, William M. Wardell, James M. Pusey

Financial Data: Fiscal Year End: 12/31 Latest Annual Data: 12/31/2006

Year	Sales	Net Income
2006	NA	-\$31,913,000
2005	NA	-\$27,202,000
2004	NA	-\$41,761,000
Curr. Assets:	\$55,974,000	Curr. Liab.: \$3,441,000
Plant, Equip.:	\$409,000	Total Liab.: \$3,441,000
Total Assets:	\$72,589,000	Net Worth: \$69,148,000

Orthometrix Inc

106 Corporate Pk. Dr., Ste. 102, White Plains, NY, 10604; **PH:** 1-914-694-2285; **Fax:** 1-914-694-2286; **http://www.orthometrix.net**; **Email:** info@orthometrix.net

General - Incorporation	DE	Stock - Price on: 12/24/2007	NA
Employees	10	Stock Exchange	OTC
Auditor	Radin, Glass & Co. LLP	Ticker Symbol	OMRX
Stk Agt	American Stock Transfer & Trust Co.	Outstanding Shares	NA
Counsel	NA	E.P.S.	-\$0.041
DUNS No.	94-423-3543	Shareholders	NA

Business: The group's principal activity is to market, sell and provide services through several musculoskeletal product lines used in pharmaceutical research, diagnosis and monitoring of bone and muscle disorders, sports medicine, rehabilitative medicine, physical therapy and pain management. Distributors and third parties are the principal customers of the group. The group also sells its products directly to end-users in those markets where the group does not have third party dealers or distributors.

Primary SIC and add'l.: 3844 3845 2834

CIK No.: 0000946428

Subsidiaries: CooperSurgical Acquisition Corp.

Officers: Reynald G. Bonmati/Chmn., CEO, Juri Schule/Customer Service Engineer, Pat Cumruff/Customer Service Engineer, Neil H. Koenig/Dir., CFO, Bruce M. Harvey/Sales Mgr. - Rehabilitation, Fitness, Ralph G. Theodore/VP - Operations, Christopher Gordon/Applications Mgr. - Pqet, Galileo, Chryste B. Zawislack/Marketing Mgr.

Directors: Reynald G. Bonmati/Chmn., CEO, William Orr/Dir., Michael W. Huber/Dir., Andre-Jacques Neusy/Dir., Neil H. Koenig/Dir., CFO, Albert S. Waxman/Dir.

Owners: William Orr, Neil H. Koenig, Michael W. Huber, Reynald G. Bonmati, Andre-Jacques Neusy, Rock Creek Investment Partners, L.P., Insiders, Psilos Group Partners II SBIC, L.P., Albert S. Waxman

Financial Data: Fiscal Year End: 12/31 Latest Annual Data: 12/31/2006

Year	Sales	Net Income
2006	\$2,362,000	-\$1,980,000
2005	\$1,515,000	-\$2,388,000
2004	\$1,180,000	-\$1,944,000
Curr. Assets:	\$1,081,000	Curr. Liab.: \$2,828,000
Plant, Equip.:	\$81,000	Total Liab.: \$3,459,000
Total Assets:	\$1,174,000	Net Worth: -\$2,286,000

Orthovita Inc

45 Great Valley Pkwy., Malvern, PA, 19355; **PH:** 1-610-640-1775; **Fax:** 1-610-640-2603; **http://www.orthovita.com**

General - Incorporation	PA	Stock - Price on: 12/24/2007	\$2.91
Employees	198	Stock Exchange	NDQ
Auditor	KPMG LLP	Ticker Symbol	VITA
Stk Agt	StockTrans, Inc.	Outstanding Shares	61,430,000
Counsel	Morgan, Lewis & Bockius LLP	E.P.S.	-\$0.3
DUNS No.	NA	Shareholders	NA

Business: The group's principal activity is to develop, manufacture and market synthetic bone substitutes for orthopaedic applications that are useful in spine and joint replacements. The products are based on two platforms: synthetic cortical bone and synthetic cancellous bone substitute. The synthetic cortical bone is a non restorable, load bearing and resin composite and the synthetic cancellous bone substitute consists of small particle restorable calcium phosphate. The products include vitoss(R) scaffold synthetic cancellous bone void filler, imbibet(tm) bone marrow aspirate syringe used with vitoss, cortoss(R) synthetic cortical bone void filler and aliquot(tm) microdelivery system used with cortoss.

Primary SIC and add'l.: 3842 3843

CIK No.: 0000913756

Subsidiaries: Partisyn Corporation, Vita Licensing, Inc, Vita Special Purpose Corporation

Officers: Antony Koblish/Dir., CEO, Pres./\$810,971.00, Maarten Penseire/Chief Medical Officer, Christopher H. Smith/Sr. VP - Sales/\$411,568.00, Douglas Low/Sr. VP - European Operations, David J. McIlhenny/Sr. VP - Operations, Albert J. Pavucek/CFO/\$78,343.00, David McIlhenny/Sr. VP - Operations/\$359,240.00

Directors: Antony Koblish/Dir., CEO, Pres., David Fitzgerald/Chmn., Mary E. Paetzold/Dir., Morris Cheston/Dir., Scott R. Barry/Dir., Paul G. Thomas/Dir., William E. Tidmore/Dir., Paul T. Touhey/Dir.

Owners: Crestview Capital Offshore Fund, Inc., Crestview Capital Fund II, LP, Crestview Capital Fund, LP, Crestview Capital Master, LLC

Financial Data: Fiscal Year End: 12/31 Latest Annual Data: 12/31/2006

Year	Sales	Net Income
2006	\$46,828,000	-\$17,464,000
2005	\$34,679,000	-\$13,363,000
2004	\$24,661,000	-\$13,198,000
Curr. Assets:	\$47,465,000	Curr. Liab.: \$8,164,000
Plant, Equip.:	\$5,295,000	Total Liab.: \$18,953,000
Total Assets:	\$62,215,000	Net Worth: \$43,262,000

Osage Federal Financial Inc

239 E Main St., Pawhuska, OK, 74056; **PH:** 1-918-287-2919

General - Incorporation	US	Stock - Price on: 12/24/2007	NA
Employees	28	Stock Exchange	NA
Auditor	BKD LLP	Ticker Symbol	NA
Stk Agt	Registrar & Transfer Co	Outstanding Shares	NA
Counsel	NA	E.P.S.	NA
DUNS No.	NA	Shareholders	NA

Business: The groups principle activity is to provide banking services and products. The group provides online banking, telephone banking, personal banking, business banking, loan products and other services. The groups personal banking services include free checking account, regular checking account, gold checking account and now checking account. The group operates from United States.

Primary SIC and add'l.: NA

CIK No.: 0001272771

Subsidiaries: Osage Federal Bank

Oscient Pharmaceuticals Corp

1000 Winter St., Ste. 2200, Waltham, MA, 02451; **PH:** 1-781-398-2300; **Fax:** 1-781-893-9535;

http://www.oscient.com; **Email:** investors@oscient.com

General - Incorporation	MA	Stock - Price on: 12/24/2007	\$4.6
Employees	336	Stock Exchange	NDQ
Auditor	Ernst & Young LLP	Ticker Symbol	OSCI
Stk Agt	Computershare Investor Services LLC	Outstanding Shares	13,760,000
Counsel	NA	E.P.S.	-\$2.32
DUNS No.	04-591-4041	Shareholders	NA

Business: The group's principal activities are to develop pharmaceutical and diagnostic products. The group concentrates the product discovery and development efforts in two principal areas, infectious diseases caused by bacterial and fungal pathogens and human diseases believed to have a significant genetic component. The group has ten ongoing product development programs. Its product candidate, ramoplanin, is in phase iii clinical trials for the prevention of bloodstream infections caused by vancomycin-resistant enterococci. It also has six product discovery and development alliances with pharmaceutical companies astrazenca, biomerieux, schering-plough and wyeth. The group also provides drug discovery services to genomvisiointm services, providing drug discovery services to pharmaceutical, biotechnology companies and national human genome research institute. The group operates solely in the domestic market. On 06-Feb-2004, the group acquired genesoft pharmaceuticals inc.

Primary SIC and add'l.: 2836 8731

CIK No.: 0000356830

Subsidiaries: Pfizer Inc, Vicuron Pharmaceuticals, Inc

Officers: Steven M. Rauscher/Dir., CEO, Pres./\$1,126,964.00, Patrick Obrien/Clerk, Joseph A. Pane/VP - Human Resources, Christopher J.M. Taylor/VP - Corporate Communications, Investor Relations, Nick Colangelo/Exec. VP - Corporate Development, Operations, Philippe M. Maitre/Sr. VP, CFO/\$300,819.00, Inder Kaul/VP - Clinical Development, Medical, Regulatory Affairs, Diane McGuire/VP - Operations, Dominick Colangelo/44/Exec. VP - Corporate Development, Operations/\$708,298.00, Aaron D. Berg/VP - Marketing, Mark A. Glickman/VP - Sales, Anthony Watkins/VP - Corporate Development

Directors: Steven M. Rauscher/Dir., CEO, Pres., David K. Stone/Chmn., Walter Flamenbaum/Dir., Robert J. Hennessey/Dir., Gary Patou/Dir., John E. Voris/Dir., Gregory B. Brown/Dir., William R. Mattson/Dir., William S. Reardon/Dir., Norbert G. Riedel/Dir.

Owners: Steven M. Rauscher/1.90%, Philippe M. Maitre, Robert J. Hennessey, David K. Stone, Gregory B. Brown, Insiders/14.80%, Walter Flamenbaum/11.90%, John E. Voris, Norbert G. Riedel, Abingworth Management Limited/5.40%, Dominick Colangelo, William R. Mattson, Paul Royalty Fund Holdings II/11.90%, William S. Reardon, Ashford Capital Management, Inc./10.90% (16

Owners included in Index)

Financial Data: Fiscal Year End: 12/31 Latest Annual Data: 12/31/2006

Year	Sales	Net Income
2006	\$46,152,000	-\$78,477,000
2005	\$23,609,000	-\$88,593,000
2004	\$6,613,000	-\$93,271,000
Curr. Assets:	\$70,234,000	Curr. Liab.: \$30,426,000
Plant, Equip.:	\$1,497,000	Total Liab.: \$281,403,000
Total Assets:	\$279,407,000	Net Worth: -\$1,996,000

Ose USA Inc

2221 Old Oakland Rd., San Jose, CA, 95131; **PH:** 1-408-383-0818

General - Incorporation	DE	Stock - Price on: 12/24/2007	NA
Employees	NA	Stock Exchange	NA
Auditor	Grant Thornton LLP	Ticker Symbol	NA
Stk Agt	NA	Outstanding Shares	NA
Counsel	NA	E.P.S.	NA
DUNS No.	80-374-3921	Shareholders	NA

Business: The group's principle activity is to operate semiconductor-packaging foundry. The group receives wafers from its customers and assembles each integrated circuit in a protective plastic package. The group operates in two segments: manufacturing and distribution. Manufacturing comprises the semiconductor packaging services of packages designed for assembly using surface mount technology in which, leads on integrated circuits are soldered to the surface of the printed circuit board. Distribution comprises the north American sales, marketing and technical support organization for ose inc. The customers of the group are manufacturers of high-tech products such as video components, chip sets, graphics chips and logic components.

Primary SIC and add'l.: 3674

CIK No.: 0000924101

Subsidiaries: OSE, Inc.

Oshkosh Truck Corp

2307 Oregon St., Oshkosh, WI, 54902; **PH:** 1-920-235-9150; **Fax:** 1-920-233-9268;

http://www.oshkoshtruckcorporation.com